High-performance liquid chromatographic assay for the determination of haloperidol in plasma

被引:7
作者
ElSayed, YM
Khidr, SH
Niazy, EM
机构
[1] Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451
关键词
D O I
10.1080/10826079608006293
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A sensitive, reproducible and accurate high performance liquid chromatographic (HPLC) method for the quantitative determination of haloperidol in plasma has been developed and validated. Sample preparation involves extraction of haloperidol and diazepam (internal standard) from 0.5 mt plasma. The separation was carried out in a stainless steel, resolve C-18 column with a mobile phase composed of a mixture of 55% methanol and 45% HPLC water containing 0.2 M ammonium acetate and adjusted to an apparent pH 7.2. The mobile phase was pumped at a flow rate of 1.5 mL/min. The column oven temperature was adjusted at 38 degrees C and the effluent was monitored at 249 nm. The retention times for the internal standard and haloperidol were found to be 5.1 and 6.3 minutes, respectively. Peak-height ratios of the drug to the internal standard were used for the quantification of haloperidol in the plasma samples. The average (+/-SD) absolute and relative recovery of haloperidol were 97+/-3.6% and 100 6+/-1.52%, respectively. The intraday coefficients of variation (CVs) ranged from 1.74 to 4.68%, while the interday CVs varied from 2.31 to 5.23%. The detection limit for haloperidol in plasma was found to be 5 ng/mL.
引用
收藏
页码:125 / 134
页数:10
相关论文
共 15 条
[1]   RAPID AND SENSITIVE METHOD FOR DETERMINATION OF HALOPERIDOL IN HUMAN SAMPLES USING NITROGEN-PHOSPHORUS SELECTIVE DETECTION [J].
BIANCHETTI, G ;
MORSELLI, PL .
JOURNAL OF CHROMATOGRAPHY, 1978, 153 (01) :203-209
[2]  
FORSMAN A, 1976, CURR THER RES CLIN E, V20, P319
[3]  
FRANKLIN M, 1980, CLIN CHEM, V26, P1367
[4]   HALOPERIDOL KINETICS AFTER ORAL AND INTRAVENOUS DOSES [J].
HOLLEY, FO ;
MAGLIOZZI, JR ;
STANSKI, DR ;
LOMBROZO, L ;
HOLLISTER, LE .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 33 (04) :477-484
[5]   MEASUREMENT OF HALOPERIDOL IN HUMAN-PLASMA USING REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
JATLOW, PI ;
MILLER, R ;
SWIGAR, M .
JOURNAL OF CHROMATOGRAPHY, 1982, 227 (01) :233-238
[6]   A COMPARISON OF DOPAMINE RECEPTOR BLOCKING ASSAY WITH PLASMA DRUG LEVELS OF HALOPERIDOL IN SCHIZOPHRENIC-PATIENTS [J].
KURLAND, AA ;
NAGARAJU, A ;
HANLON, TE ;
WILKINSON, EH ;
NG, KT .
JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 21 (01) :42-47
[7]   AN ULTRASENSITIVE METHOD FOR THE MEASUREMENT OF HALOPERIDOL AND REDUCED HALOPERIDOL IN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH COULOMETRIC DETECTION [J].
MIDHA, KK ;
COOPER, JK ;
HAWES, EM ;
HUBBARD, JW ;
KORCHINSKI, ED ;
MCKAY, G .
THERAPEUTIC DRUG MONITORING, 1988, 10 (02) :177-183
[8]   MEASUREMENT OF HALOPERIDOL AND REDUCED HALOPERIDOL IN HUMAN-PLASMA USING REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
MILLER, RL ;
DEVANE, CL .
JOURNAL OF CHROMATOGRAPHY, 1986, 374 (02) :405-408
[9]   HALOPERIDOL PLASMA-LEVEL MONITORING IN NEUROPSYCHIATRIC PATIENTS [J].
MORSELLI, PL ;
BIANCHETTI, G ;
DUGAS, M .
THERAPEUTIC DRUG MONITORING, 1982, 4 (01) :51-58
[10]   ISOLATION AND IDENTIFICATION OF A METABOLITE OF HALOPERIDOL [J].
PAPE, BE .
JOURNAL OF ANALYTICAL TOXICOLOGY, 1981, 5 (03) :113-117